Skip to main content
Father's Day Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

FDA Approves Gadoquatrane to Detect CNS and Non-CNS Body Region Lesions

Summary by cancernetwork.com
The FDA has approved gadoquatrane for contrast-enhanced MRI to detect lesions with abnormal vascularity in the central nervous system and body.

4 Articles

Post RegisterPost Register
+2 Reposted by 2 other sources
Center

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 15, 2026-

Read Full Article
cancernetwork.comcancernetwork.com

FDA Approves Gadoquatrane to Detect CNS and Non-CNS Body Region Lesions

The FDA has approved gadoquatrane for contrast-enhanced MRI to detect lesions with abnormal vascularity in the central nervous system and body.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

mykxlg.com broke the news on Monday, June 15, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

FDA icon

FDA

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal